US ‘Lags Behind’ EU & Canada On Clinical Data Transparency
Health Canada Found To Offer The Most Efficient Source Of Regulatory Data
Executive Summary
The US Food and Drug Administration has proactively released data for just one drug, compared with data released for over 100 drugs by the European Medicines Agency and just over 70 drugs by Health Canada, according to a study that compared the accessibility and comprehensiveness of the data that the three regulators proactively or reactively disclose.
You may also be interested in...
EMA To Focus On Filings For Novel Drugs Under Restart Of Trial Transparency Policy
The European Medicines Agency is working on restarting its landmark policy on publishing clinical trial data, with the first phase expected to start this year.
Health Canada Ponders UK Model On Easing Biosimilar Study Requirements
Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.
Ophthalmic Bevacizumab & CRISPR-Based Gene Therapy Among Latest EU Filings
Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.